A share price of Moderna Inc [MRNA] is currently trading at $25.0, up 0.64%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MRNA shares have gain 2.84% over the last week, with a monthly amount drifted -11.00%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Moderna Inc [NASDAQ: MRNA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Neutral rating and assigned the stock a price target of $40. Previously, Barclays downgraded its rating to Equal Weight on February 18, 2025, and dropped its price target to $45. On January 29, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $51 on the stock. Argus downgraded its rating to a Hold. Berenberg started tracking with a Hold rating for this stock on November 19, 2024, and assigned it a price target of $42. In a note dated November 18, 2024, HSBC Securities upgraded an Buy rating on this stock but restated the target price of $58.
Moderna Inc experienced fluctuations in its stock price throughout the past year between $23.15 and $75.37. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Moderna Inc [NASDAQ: MRNA] shares were valued at $25.0 at the most recent close of the market. An investor can expect a potential return of 16.0% based on the average MRNA price forecast.
Analyzing the MRNA fundamentals
Trailing Twelve Months sales for Moderna Inc [NASDAQ:MRNA] were 3.08B which represents -41.08% decline. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at -1.07%, Pretax Profit Margin comes in at -0.96%, and Net Profit Margin reading is -0.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.27 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Moderna Inc [NASDAQ:MRNA] is 3.93. Further, the Quick Ratio stands at 3.77, while the Cash Ratio is 0.81. Considering the valuation of this stock, the price to sales ratio is 3.16, the price to book ratio is 1.03.
Transactions by insiders
Recent insider trading involved Hussain Abbas, Director, that happened on Jun 11 ’25 when 312.0 shares were sold. Director, Hussain Abbas completed a deal on Jun 11 ’25 to buy 312.0 shares. Meanwhile, Chief Executive Officer Bancel Stephane bought 0.16 million shares on Mar 03 ’25.
